Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 90 of 95, showing 5 Applications out of 471 total, starting on record 446, ending on 450

# Protocol No Study Title Investigator(s) & Site(s)

446.

ECCT/24/02/09   pionERA
    This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of   giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor   (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal   growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant   endocrine therapy.   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

447.

ECCT/24/02/10   IMBrave
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA   
Principal Investigator(s)
1. Dr. Pauline Njoki Njiraini
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

448.

ECCT/24/03/02   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr. Janet Nyawira Oyieko
Site(s) in Kenya
1. KEMRI CCR – Butere Clinical Research Centre (Kakamega county)
 
View

449.

ECCT/24/03/03   DoxyDOT Study
    Weekly doxycycline DOT for STI prevention among cisgender women taking HIV PrEP in Kisumu, Kenya   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI CMR RCTP
 
View

450.

ECCT/24/03/04   MK8591A-053 Trial
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
2. Nelly Rwamba Mugo
Site(s) in Kenya
1. Site 8650, KEMRI-CMR-RCTP, Kisumu (Kisumu county)
2. Site 8651, KEMRI-CCR-PHRD, Thika (Kiambu county)
3. Site 8652, KEMRI-CCR, NAIROBI (Nairobi City county)
 
View